Fatigue is not associated with raised inflammatory markers in multiple sclerosis

被引:62
作者
Giovannoni, G
Thompson, AJ
Miller, DH
Thompson, EJ
机构
[1] UCL Inst Neurol, Dept Neurochem, London WC1N 3BG, England
[2] UCL Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England
[3] UCL Inst Neurol, Dept Neurorehabil, London WC1N 3BG, England
关键词
D O I
10.1212/WNL.57.4.676
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The pathogenesis of fatigue in patients with MS is poorly understood. Objective: To test the hypothesis that fatigue in MS is related to inflammatory disease activity as measured by systemic markers of inflammation. Methods: Fatigue as assessed by the Fatigue Questionnaire Scale (FQS) and Krupp's Fatigue Severity Scale (KFSS) was correlated with several inflammatory markers in 38 patients with MS (16 relapsing-remitting [RR; 7 of whom had benign MS), 9 secondary progressive [SP], 13 primary progressive [PPI). The markers included daily urinary neopterin excretion, a marker of interferon-gamma -activated macrophage activity, and serum C-reactive protein (CRP) and soluble intercellular adhesion molecule-1 (sICAM-1) levels. Urinary neopterin excretion was measured daily for 2 weeks. Results: No correlation was found between urinary neopterin excretion, CRP, or sICAM-1 and the fatigue scores. However, patients with a raised serum CRP level had higher KFSS, but not FQS, scores than patients with normal CRP levels (KFSS, 50 8 vs 41 +/- 14, p = 0.05; FQS, 13 +/- 4 vs 11 +/- 5, p = NS). When assessed using the FQS, patients with RR and SP MS were more fatigued than patients with PP MS (RR = 12.5 [4 to 23] vs SP = 13 [8 to 18] vs PP = 9 [7 to 14], p = 0.02). The patients with benign MS were as fatigued as patients with nonbenign disease. Conclusion: The pathogenesis of fatigue in MS is complex and does not appear to be directly related to systemic markers of inflammatory disease activity. Interestingly, patients with PP MS were less fatigued than patients with RR disease.
引用
收藏
页码:676 / 681
页数:6
相关论文
共 39 条
[2]  
AUZEBY A, 1988, CLIN CHEM, V34, P866
[3]   Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients [J].
Bakshi, R ;
Miletich, RS ;
Henschel, K ;
Shaikh, ZA ;
Janardhan, V ;
Wasay, M ;
Stengel, LM ;
Ekes, R ;
Kinkel, PR .
NEUROLOGY, 1999, 53 (05) :1151-1153
[4]  
BERTOLONE K, 1993, NEUROLOGY, V43, pA356
[5]   COGNITIVE BEHAVIOR-THERAPY IN CHRONIC FATIGUE SYNDROME [J].
BUTLER, S ;
CHALDER, T ;
RON, M ;
WESSELY, S .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (02) :153-158
[6]   DEVELOPMENT OF A FATIGUE SCALE [J].
CHALDER, T ;
BERELOWITZ, G ;
PAWLIKOWSKA, T ;
WATTS, L ;
WESSELY, S ;
WRIGHT, D ;
WALLACE, EP .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 1993, 37 (02) :147-153
[7]   SLEEP DISTURBANCE, DEPRESSION, AND LESION SITE IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
CLARK, CM ;
FLEMING, JA ;
LI, D ;
OGER, J ;
KLONOFF, H ;
PATY, D .
ARCHIVES OF NEUROLOGY, 1992, 49 (06) :641-643
[8]   MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue [J].
Colombo, B ;
Boneschi, FM ;
Rossi, P ;
Rovaris, M ;
Maderna, L ;
Filippi, M ;
Comi, G .
JOURNAL OF NEUROLOGY, 2000, 247 (07) :506-509
[9]   Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment [J].
Djaldetti, R ;
Ziv, I ;
Achiron, A ;
Melamed, E .
NEUROLOGY, 1996, 46 (03) :632-635
[10]   RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
KALDEN, JR ;
ANTONI, C ;
SMOLEN, JS ;
LEEB, B ;
BREEDVELD, FC ;
MACFARLANE, JD ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1105-1110